Literature DB >> 23592565

Impact of statin use on lipid levels in statin-naive patients with rheumatoid arthritis versus non-rheumatoid arthritis subjects: results from a population-based study.

Elena Myasoedova1, Sherine E Gabriel, Abigail B Green, Eric L Matteson, Cynthia S Crowson.   

Abstract

OBJECTIVE: To examine lipid profiles among statin-naive patients with rheumatoid arthritis (RA) and those without RA before and after the initiation of statins.
METHODS: Information regarding lipid measures and statin use was gathered in a population-based incident cohort of patients with RA (1987 American College of Rheumatology criteria first met between January 1, 1988 and January 1, 2008) and in a cohort of non-RA subjects from the same underlying population. Only patients with no prior history of statin use were included.
RESULTS: The study included 161 patients with RA (mean age 56.3 years, 57% female) and 221 non-RA subjects (mean age 56.0 years, 66% female). Prior to the start of statins, the levels of total cholesterol and low-density lipoprotein (LDL) cholesterol were lower in the RA versus the non-RA cohort (P < 0.001 and P = 0.003, respectively). The absolute and percentage change in LDL cholesterol after at least 90 days of statin use tended to be smaller in the RA versus the non-RA cohort (P = 0.03 and P = 0.09, respectively). After at least 90 days of statin use, patients with RA were less likely to achieve therapeutic goals for LDL cholesterol than the non-RA subjects (P = 0.046). Increased erythrocyte sedimentation rate (ESR) at baseline (odds ratio 0.47, 95% confidence interval 0.26-0.85) was associated with lower likelihood of achieving therapeutic LDL goals.
CONCLUSION: Patients with RA had lower total cholesterol and LDL cholesterol levels before statin initiation and lower likelihood of achieving therapeutic LDL goals following statin use than the non-RA subjects. Some RA disease characteristics, in particular ESR at baseline, may have an adverse impact on achieving therapeutic LDL goals.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23592565      PMCID: PMC3788038          DOI: 10.1002/acr.22029

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  26 in total

1.  History of the Rochester Epidemiology Project.

Authors:  L J Melton
Journal:  Mayo Clin Proc       Date:  1996-03       Impact factor: 7.616

2.  Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.

Authors:  Jennifer G Robinson; Brian Smith; Nidhi Maheshwari; Helmut Schrott
Journal:  J Am Coll Cardiol       Date:  2005-10-24       Impact factor: 24.094

3.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

Review 4.  Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.

Authors:  Steven E Nissen
Journal:  Am J Cardiol       Date:  2005-09-05       Impact factor: 2.778

5.  Extra-articular rheumatoid arthritis: prevalence and mortality.

Authors:  C Turesson; L Jacobsson; U Bergström
Journal:  Rheumatology (Oxford)       Date:  1999-07       Impact factor: 7.580

6.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Authors:  T A Pearson; I Laurora; H Chu; S Kafonek
Journal:  Arch Intern Med       Date:  2000-02-28

Review 7.  Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.

Authors:  Hilal Maradit-Kremers; Cynthia S Crowson; Paulo J Nicola; Karla V Ballman; Véronique L Roger; Steve J Jacobsen; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2005-02

8.  Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.

Authors:  David W McCarey; Iain B McInnes; Rajan Madhok; Rosie Hampson; Olga Scherbakov; Ian Ford; Hilary A Capell; Naveed Sattar
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

Review 9.  Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?

Authors:  Uwe Schönbeck; Peter Libby
Journal:  Circulation       Date:  2004-06-01       Impact factor: 29.690

10.  Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic.

Authors:  Silvia Rollefstad; Tore K Kvien; Ingar Holme; Anne S Eirheim; Terje R Pedersen; Anne Grete P Semb
Journal:  Ann Rheum Dis       Date:  2012-12-22       Impact factor: 19.103

View more
  7 in total

Review 1.  Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure.

Authors:  Kerry Wright; Cynthia S Crowson; Sherine E Gabriel
Journal:  Heart Fail Clin       Date:  2014-01-10       Impact factor: 3.179

2.  Use of Hydroxychloroquine Is Associated With Improved Lipid Profile in Rheumatoid Arthritis Patients.

Authors:  Jose Felix Restrepo; Inmaculada Del Rincon; Emily Molina; Daniel F Battafarano; Agustin Escalante
Journal:  J Clin Rheumatol       Date:  2017-04       Impact factor: 3.517

Review 3.  Cardiac Impairment in Rheumatoid Arthritis and Influence of Anti-TNFα Treatment.

Authors:  Ivica Lazúrová; Ľubomír Tomáš
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

Review 4.  Atherosclerotic vascular disease in the autoimmune rheumatologic woman.

Authors:  Reto Daniel Kurmann; Rekha Mankad
Journal:  Clin Cardiol       Date:  2018-02-26       Impact factor: 2.882

Review 5.  Atherosclerosis in rheumatoid arthritis: is it all about inflammation?

Authors:  Sarah Skeoch; Ian N Bruce
Journal:  Nat Rev Rheumatol       Date:  2015-03-31       Impact factor: 20.543

Review 6.  Lipid and Metabolic Changes in Rheumatoid Arthritis.

Authors:  Catherine M McGrath; Stephen P Young
Journal:  Curr Rheumatol Rep       Date:  2015-09       Impact factor: 4.592

Review 7.  The Role of Statins in Disease Modification and Cardiovascular Risk in Rheumatoid Arthritis.

Authors:  Stergios Soulaidopoulos; Elena Nikiphorou; Theodoros Dimitroulas; George D Kitas
Journal:  Front Med (Lausanne)       Date:  2018-02-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.